CCL2 and prostate cancer: Previous studies have demonstrated that Carlumab (CNTO 888), which is a human IgG1κ monoclonal antibody with high affinity and specificity for human CCL2, does not inhibit the CCL2/CCR2 axis or demonstrate antitumor activity as a single agent in metastatic castration-resistant prostate cancer (27).